Becker's Healthcare August 2, 2024
There has been an uptick in patients being treated for eating disorders who are abusing GLP-1 drugs like Ozempic, Mounjaro and Wegovy, according to research published Aug. 1 in the Journal of Clinical Psychopharmacology.
Two separate studies — one focusing on semaglutide misuse in patients with atypical anorexia nervosa, the other on GLP-1 weight loss drug use in patients with bipolar disorder or eating disorders — “alert clinicians of the importance of reviewing patients and medical and psychiatric histories, being attuned to patient histories of weight fluctuations, and screening for eating dysregulation when prescribing weight-loss approved medications,” authors wrote.
In one study, a patient with anorexia who misused semaglutide lost 40 pounds in nine months. In the other study, researchers...
Today's Sponsors
Today's Sponsor